Answers are grounded in this paper and cite their sources.
Osteosarcoma remains refractory to immunotherapy due to its immunologically "cold" tumour microenvironment (TME), characterised by insufficient immune infiltration and potent immunosuppression. Nanocarriers have emerged as versatile platforms integrating therapeutic and immunomodulatory functions to remodel this microenvironment. This review outlines strategies for transforming osteosarcoma from "cold" to "hot." We first dissect key immunosuppressive components of the osteosarcoma TME, then analyse how cell death pathways—ferroptosis, cuproptosis, PANoptosis, and autophagy—trigger immunogenic cell death (ICD) and innate immune activation. We critically evaluate three nanocarrier classes—inorganic (metal-based, hydroxyapatite, piezoelectric), organic (polymer, lipid, protein, gelatin), and hybrid platforms (metal–organic frameworks, metal–phenolic networks, MXenes, and cell membrane-coated nanoparticles)—focusing on immune activation mechanisms and preclinical evidence. Finally, we highlight four paradigm shifts and discuss critical bottlenecks hindering clinical translation, providing a rational framework for designing next-generation nanocarrier-based immunotherapies for osteosarcoma.
No takes yet. Share an insight, caveat, or question.
Fu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: